" class="no-js "lang="en-US"> Greg Hannon - Medtech Alert
Tuesday, August 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Greg Hannon

Greg Hannon

About Greg Hannon

  • Active Director of the Cancer Research UK Cambridge Institute.
  • Internationally recognized and awarded for his contributions to small RNA biology, cancer biology, and mammalian genomics.
  • Most proud of the long list of scientists he trained and supported through his career – which include Eleven’s CEO.

Related Story

Artificial Intelligence

 Eleven Therapeutics Announces $22 Million in Seed Funding | Pharmtech Focus

Eleven Therapeutics Announces $22 Million in Seed Funding

August 3 2022

Eleven Therapeutics, a biotechnology company leading the AI revolution in nucleic acid therapeutics, announced today […]